These findings further suggest that some of the beneficial effects of MR antagonists in improving cardiac function and preventing mortality in HF patients could be independent of effects on cardiac hypertrophy or fibrosis but rather could involve regulation of proinflammatory cytokines and/or endothelin signaling in the heart or coronary vasculature. Here, NR3C2 is linked to cardiac hypertrophy.